<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02652988</url>
  </required_header>
  <id_info>
    <org_study_id>14-0471</org_study_id>
    <nct_id>NCT02652988</nct_id>
  </id_info>
  <brief_title>Home-based Transcranial Direct Current Stimulation in Fibromyalgia Patients</brief_title>
  <official_title>Home-based Transcranial Direct Current Stimulation in Fibromyalgia Patients. Phase II, Randomized, Double-blind, Single-center Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wolnei Caumo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this phase II, randomized, double-blind clinical trial, the investigators intended to
      evaluate the home-based effect of transcranial direct current stimulation (tDCS) in patients
      with fibromyalgia. This syndrome affects between 3-5% of the population in an age group 40-60
      years also occurring in childhood and old age. Reaches 3.4% of women and 0.5% of men.
      Fibromyalgia is a chronic widespread pain syndrome in various parts of the body. The
      neuromodulation techniques have as a principle produce inhibition or cortical arousal. The
      tDCS is a non-invasive brain stimulation method used to modulate the cortical excitability,
      using a low intensity direct current (1-2mA) directed to the scalp via the cathode and anode
      electrodes. The current reaches the cortex, producing hyperpolarization or depolarization of
      the axonal membrane potential. Evidence has shown that this method is presented as a
      technique able to alter cortical and subcortical neural networks. This technique has been
      used to treat psychiatric disorders such as depression, acute mania, bipolar affective
      disorder, panic, hallucinations, obsessive compulsive disorder, schizophrenia, withdrawal,
      rehabilitation after stroke, pain syndromes such as neuropathic pain, migraine, pancreatitis
      pain chronic and fibromyalgia. The tDCS is a low cost technique, with virtually no side
      effects and which exerts therapeutic effect by neuromodulatory pathways by distinct pathways
      activated by the drugs. In this scenario falls within the importance of developing this
      device for home use by fibromyalgia patients, since it is easy to use and thereby enables
      maintaining the benefit observed in studies performed and supervised frequently used in care
      centers. The use of tDCS over the long term is not feasible in hospital by patients demands,
      sometimes every day or more than once a week, removing the patient from their activities, and
      cost shifting and overload the healthcare system. Therefore, the objective of this study is
      to evaluate the effect of home-based tDCS in fibromyalgia patients in long-term treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Will be included women aged between 18 and 65 years, chronic pain fibromyalgia according to
      the criteria of the American College of Rheumatology, pain unresponsive to analgesics such as
      paracetamol, acetylsalicylic acid, ibuprofen, Carisoprodol, Zanaflex (Tizanidine) and
      Codeine. And give informed consent to participate after initial evaluation. Primary outcome
      is to evaluate the effect of treatment with home-base tDCS in patients with fibromyalgia.
      Secondary outcomes are: compare the effect of active home-based tDCS and sham in cortical
      neurophysiological processes and subcortical to stimulation with TMS and standardized noxious
      stimuli with and without concomitant conditioned Pain Modulation (CPM) in pain threshold
      outcomes to the test mechanical pressure, heat-algesic stimulus, cortical excitability
      parameters [evoked rest motor (MEP) MEP enough to evoke amplitude of 1 mV peak to peak,
      silent period (SP), motor threshold (MT), variation in blood volume and oxygenation cortical
      motor area [oxy-hemoglobin concentrations (Hbo) / deoxy-hemoglobin (HBr)] optically
      functional neuroimaging (NIRS) and variation in the frequency of alpha and beta waves of
      motor area stimulated by tDCS assessed by electroencephalogram (EEG). In surrogate outcome,
      the investigators will compare the effect of active home-sham tDCS the tDCS in pain levels
      and functional capacity, catastrophic thinking, bookmark levels of neurotrophic activity
      (BDNF) and astrocytic (S100 beta).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain level in fibromyalgia patients using home-based tDCS</measure>
    <time_frame>Ffive days per week, during 12 weeks.</time_frame>
    <description>Evaluate the level of pain in fibromyalgia patients before and after each home-based tDCS session. We will use numerical pain scale to do that.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cortical excitability on the transcranial magnetic stimulation (TMS)</measure>
    <time_frame>2 days</time_frame>
    <description>Evaluation of the variation in cortical excitability parameters pre and pos application of home-based tDCS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of Brain Derived Neurotrophic Factor (BDNF)</measure>
    <time_frame>2 days</time_frame>
    <description>Measurement of serum levels of BDNF pre and pos application of home-based tDCS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of calcium-binding protein B (S100B)</measure>
    <time_frame>2 days</time_frame>
    <description>Measurement of serum levels of S100B pre and pos application of home-based tDCS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional capacity</measure>
    <time_frame>2 days</time_frame>
    <description>Measurement of functional capacity pre and pos application of home-based tDCS with functional capacity scale in chronic pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Catastrophic thinking</measure>
    <time_frame>2 days</time_frame>
    <description>Measurement of catastrophic thinking pre and pos application of home-based tDCS with catastrophizing scale.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Active-tDCs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>17 patients will receive Active-tDCS intervention (2mA, 20 min) at home.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham-tDCS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>17 patients will receive Sham-tDCS intervention (2mA, 20 min) at home.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Active-tDCS</intervention_name>
    <description>Active home-based tDCS applied at home.</description>
    <arm_group_label>Active-tDCs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham-tDCS</intervention_name>
    <description>Sham home-based tDCS applied at home.</description>
    <arm_group_label>Sham-tDCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  have chronic pain fibromyalgia according to the criteria of the American College of
             Rheumatology

          -  Pain unresponsive to analgesics such as paracetamol, acetyl salicylic acid, Ibuprofen,
             Carisoprodol, Zanaflex (Tizanidine) and Codeine

          -  Give informed consent to participate after initial evaluation.

        Exclusion Criteria:

          -  Pregnancy

          -  Treatment with carbamazepine and gabapentin

          -  The. Metallic implant in the brain

          -  Medical devices implanted in the brain

          -  Alcohol or drug abuse history in the last 6 months

          -  Suffering from severe depression (with score&gt; 30 on the Beck Depression Inventory)

          -  History of neurological disorders

          -  Unexplained fainting History

          -  History of head trauma or momentary loss of consciousness (self reported)

          -  Neurosurgery History

          -  Decompensated systemic diseases, and chronic inflammatory diseases (lupus, rheumatoid
             arthritis, renal failure and hepatitis).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolnei S Calmo, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wolnei Caumo, Ph.D</last_name>
    <email>wcaumo@cpovo.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aline Brietzke, MD</last_name>
    <email>aline_brietzke@yahoo.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90.450-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolnei Caumo, PhD</last_name>
      <phone>+5551 3359 8083</phone>
      <email>wcaumo@hcpa.edu.br</email>
    </contact>
    <investigator>
      <last_name>Wolnei Caumo, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wolnei Caumo</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aline Brietzke, PhD</last_name>
      <phone>5551 996097850</phone>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Arnold LM. Biology and therapy of fibromyalgia. New therapies in fibromyalgia. Arthritis Res Ther. 2006;8(4):212. Review.</citation>
    <PMID>16762044</PMID>
  </reference>
  <reference>
    <citation>Ablin J, Fitzcharles MA, Buskila D, Shir Y, Sommer C, Häuser W. Treatment of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines with special emphasis on complementary and alternative therapies. Evid Based Complement Alternat Med. 2013;2013:485272. doi: 10.1155/2013/485272. Epub 2013 Nov 21. Review.</citation>
    <PMID>24348701</PMID>
  </reference>
  <reference>
    <citation>Bigatti SM, Hernandez AM, Cronan TA, Rand KL. Sleep disturbances in fibromyalgia syndrome: relationship to pain and depression. Arthritis Rheum. 2008 Jul 15;59(7):961-7. doi: 10.1002/art.23828.</citation>
    <PMID>18576297</PMID>
  </reference>
  <reference>
    <citation>Boggio PS, Rigonatti SP, Ribeiro RB, Myczkowski ML, Nitsche MA, Pascual-Leone A, Fregni F. A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression. Int J Neuropsychopharmacol. 2008 Mar;11(2):249-54. Epub 2007 Jun 11.</citation>
    <PMID>17559710</PMID>
  </reference>
  <reference>
    <citation>Bradley LA, Wohlreich MM, Wang F, Gaynor PJ, Robinson MJ, D'Souza DN, Mease PJ. Pain response profile of patients with fibromyalgia treated with duloxetine. Clin J Pain. 2010 Jul-Aug;26(6):498-504. doi: 10.1097/AJP.0b013e3181dee80e.</citation>
    <PMID>20551724</PMID>
  </reference>
  <reference>
    <citation>Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001 Dec;25(6):871-80.</citation>
    <PMID>11750180</PMID>
  </reference>
  <reference>
    <citation>Burgmer M, Pogatzki-Zahn E, Gaubitz M, Wessoleck E, Heuft G, Pfleiderer B. Altered brain activity during pain processing in fibromyalgia. Neuroimage. 2009 Jan 15;44(2):502-8. doi: 10.1016/j.neuroimage.2008.09.008. Epub 2008 Sep 24.</citation>
    <PMID>18848998</PMID>
  </reference>
  <reference>
    <citation>Clauw DJ. Fibromyalgia: an overview. Am J Med. 2009 Dec;122(12 Suppl):S3-S13. doi: 10.1016/j.amjmed.2009.09.006. Review.</citation>
    <PMID>19962494</PMID>
  </reference>
  <reference>
    <citation>Chappell AS, Bradley LA, Wiltse C, Detke MJ, D'Souza DN, Spaeth M. A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med. 2008 Nov 30;1:91-102.</citation>
    <PMID>20428412</PMID>
  </reference>
  <reference>
    <citation>Chen R, Samii A, Caños M, Wassermann EM, Hallett M. Effects of phenytoin on cortical excitability in humans. Neurology. 1997 Sep;49(3):881-3.</citation>
    <PMID>9305361</PMID>
  </reference>
  <reference>
    <citation>Fregni F, Gimenes R, Valle AC, Ferreira MJ, Rocha RR, Natalle L, Bravo R, Rigonatti SP, Freedman SD, Nitsche MA, Pascual-Leone A, Boggio PS. A randomized, sham-controlled, proof of principle study of transcranial direct current stimulation for the treatment of pain in fibromyalgia. Arthritis Rheum. 2006 Dec;54(12):3988-98.</citation>
    <PMID>17133529</PMID>
  </reference>
  <reference>
    <citation>Fregni F, Boggio PS, Nitsche MA, Marcolin MA, Rigonatti SP, Pascual-Leone A. Treatment of major depression with transcranial direct current stimulation. Bipolar Disord. 2006 Apr;8(2):203-4.</citation>
    <PMID>16542193</PMID>
  </reference>
  <reference>
    <citation>Fregni F, Boggio PS, Nitsche M, Pascual-Leone A. Transcranial direct current stimulation. Br J Psychiatry. 2005 May;186:446-7.</citation>
    <PMID>15863752</PMID>
  </reference>
  <reference>
    <citation>Giesecke T, Williams DA, Harris RE, Cupps TR, Tian X, Tian TX, Gracely RH, Clauw DJ. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum. 2003 Oct;48(10):2916-22.</citation>
    <PMID>14558098</PMID>
  </reference>
  <reference>
    <citation>Harris RE, Clauw DJ. Newer treatments for fibromyalgia syndrome. Ther Clin Risk Manag. 2008 Dec;4(6):1331-42.</citation>
    <PMID>19337439</PMID>
  </reference>
  <reference>
    <citation>Lindell L, Bergman S, Petersson IF, Jacobsson LT, Herrström P. Prevalence of fibromyalgia and chronic widespread pain. Scand J Prim Health Care. 2000 Sep;18(3):149-53.</citation>
    <PMID>11097099</PMID>
  </reference>
  <reference>
    <citation>Manganotti P, Bongiovanni LG, Zanette G, Turazzini M, Fiaschi A. Cortical excitability in patients after loading doses of lamotrigine: a study with magnetic brain stimulation. Epilepsia. 1999 Mar;40(3):316-21.</citation>
    <PMID>10080512</PMID>
  </reference>
  <reference>
    <citation>Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl. 2005 Aug;75:6-21. Review. Erratum in: J Rheumatol Suppl. 2005 Oct;32(10):2063.</citation>
    <PMID>16078356</PMID>
  </reference>
  <reference>
    <citation>Moore RA, Cai N, Skljarevski V, Tölle TR. Duloxetine use in chronic painful conditions--individual patient data responder analysis. Eur J Pain. 2014 Jan;18(1):67-75. doi: 10.1002/j.1532-2149.2013.00341.x. Epub 2013 Jun 3.</citation>
    <PMID>23733529</PMID>
  </reference>
  <reference>
    <citation>Roizenblatt S, Fregni F, Gimenez R, Wetzel T, Rigonatti SP, Tufik S, Boggio PS, Valle AC. Site-specific effects of transcranial direct current stimulation on sleep and pain in fibromyalgia: a randomized, sham-controlled study. Pain Pract. 2007 Dec;7(4):297-306. Epub 2007 Nov 6.</citation>
    <PMID>17986164</PMID>
  </reference>
  <reference>
    <citation>Schestatsky P, Stefani LC, Sanches PR, Silva Júnior DP, Torres IL, Dall-Agnol L, Balbinot LF, Caumo W. Validation of a Brazilian quantitative sensory testing (QST) device for the diagnosis of small fiber neuropathies. Arq Neuropsiquiatr. 2011 Dec;69(6):943-8.</citation>
    <PMID>22297885</PMID>
  </reference>
  <reference>
    <citation>Staud R. Treatment of fibromyalgia and its symptoms. Expert Opin Pharmacother. 2007 Aug;8(11):1629-42. Review.</citation>
    <PMID>17685881</PMID>
  </reference>
  <reference>
    <citation>Staud R, Smitherman ML. Peripheral and central sensitization in fibromyalgia: pathogenetic role. Curr Pain Headache Rep. 2002 Aug;6(4):259-66. Review.</citation>
    <PMID>12095460</PMID>
  </reference>
  <reference>
    <citation>Valle A, Roizenblatt S, Botte S, Zaghi S, Riberto M, Tufik S, Boggio PS, Fregni F. Efficacy of anodal transcranial direct current stimulation (tDCS) for the treatment of fibromyalgia: results of a randomized, sham-controlled longitudinal clinical trial. J Pain Manag. 2009;2(3):353-361.</citation>
    <PMID>21170277</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2015</study_first_submitted>
  <study_first_submitted_qc>January 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2016</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Clinicas de Porto Alegre</investigator_affiliation>
    <investigator_full_name>Wolnei Caumo</investigator_full_name>
    <investigator_title>Wolnei Caumo</investigator_title>
  </responsible_party>
  <keyword>tDCS</keyword>
  <keyword>chronic pain</keyword>
  <keyword>fibromyalgia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

